metabolic · Mechanism Report
Does vitamin D need liver hydroxylation before kidney activation?
Vitamin D is first hydroxylated in the liver and then activated in the kidney.
This is what AI claimed
Vitamin D is hydroxylated in the liver before kidney activation, so hepatobiliary stress signals such as elevated gamma-glutamyl transferase and bilirubin are relevant to vitamin D handling.
Executive summary
The claim describes vitamin D metabolism as a two-step process, with the liver producing circulating 25-hydroxyvitamin D before renal conversion to the active hormone. It also frames elevated gamma-glutamyl transferase and bilirubin as contextual markers that may point to hepatobiliary disease, which can affect vitamin D handling indirectly. The graph emphasizes that these liver tests are not direct measures of vitamin D status on their own.
Verified conclusion
Vitamin D metabolism is sequential: hepatic processing generates the main circulating substrate, followed by predominantly renal hormonal activation. The relevance of liver-test abnormalities is therefore contextual, strongest when they indicate clinically meaningful cholestatic or chronic liver disease.
Mechanistic evidence
- Vitamin D₃ is first 25-hydroxylated predominantly in the liver, principally by CYP2R1, producing 25-hydroxyvitamin D [25(OH)D; calcidiol], the principal circulating form and standard clinical status marker.
- 25(OH)D is then converted mainly in renal proximal tubules by mitochondrial CYP27B1 to 1,25-dihydroxyvitamin D [calcitriol], the active hormone. Parathyroid hormone stimulates this step, whereas FGF23 and calcitriol suppress it; CYP24A1 degrades both metabolites.
- Thus, the liver-to-kidney sequence is well established, although other hepatic 25-hydroxylases and extra-renal CYP27B1 expression contribute in limited contexts.
Hepatobiliary markers and vitamin-D interpretation
- Elevated GGT or bilirubin can be relevant because they may signal cholestasis or chronic/advanced liver disease. Cholestasis can reduce bile-salt-dependent intestinal absorption of fat-soluble vitamin D and may alter hepatic and vitamin-D-transport protein physiology.
- Neither marker should be treated as a direct measure of vitamin-D status. Adjusted NHANES data and a study in overweight/obese adults without liver disease found no independent GGT–25(OH)D association; a coronary-disease cohort found an inverse association but has limited generalizability.
- Hyperbilirubinemia itself does not appear to block hepatic 25-hydroxylation: acute obstructive-jaundice patients generally retained normal 25(OH)D and conversion. In established liver disease, reduced albumin or vitamin-D-binding protein can lower total 25(OH)D without an equivalent fall in bioavailable vitamin D.
Bottom line
- The metabolic sequence is strongly established; GGT and bilirubin are useful contextual clues to underlying hepatobiliary disease, not standalone evidence of impaired vitamin-D handling or deficiency.
References
- Vitamin D Metabolism, Mechanism of Action, and Clinical ... — pmc.ncbi.nlm.nih.gov
- Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase | PNAS — pnas.org
- Metabolism of vitamin D by human microsomal CYP2R1 — sciencedirect.com
- Vitamin D metabolism revised: fall of dogmas — pmc.ncbi.nlm.nih.gov
- CYP2R1 is a major, but not exclusive, contributor to 25 ... - PNAS — pnas.org
- Serum Gamma Glutamyltransferase Is Associated with 25 ... - PMC — pmc.ncbi.nlm.nih.gov
- Table 1 — pmc.ncbi.nlm.nih.gov
- Vitamin D deficiency in chronic liver disease - PMC - NIH — pmc.ncbi.nlm.nih.gov
- Vitamin D metabolism in acute and chronic cholestasis - PubMed — pubmed.ncbi.nlm.nih.gov
See a full patient report verified like this
Book a walkthrough